Patents Assigned to Aerie Pharmaceuticals, Inc.
-
Patent number: 10849656Abstract: Embodiments described herein relate generally to medical implant delivery apparatuses and methods. In some embodiments, an apparatus comprises a first cap, a needle hub at least partially disposed within the first cap, a pusher wire and a pusher wire connector disposed within the needle hub, a needle and a second cap. The first cap includes a proximal end, a distal end, and a longitudinal axis. The needle includes a first, beveled end configured to receive an implant, and a second end disposed within a hub pocket of the needle hub. The second cap is connected to the needle hub and disposed at a proximal end of the first cap. The pusher wire, the pusher wire connector, and the needle are substantially aligned with one another along the longitudinal axis of the first cap. In some embodiments, the pusher wire is sized to be received in the bore of the needle.Type: GrantFiled: September 5, 2017Date of Patent: December 1, 2020Assignee: Aerie Pharmaceuticals, Inc.Inventors: Tomas Navratil, Jessie Delgado, Michael Hunter
-
Patent number: 10654844Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.Type: GrantFiled: June 7, 2019Date of Patent: May 19, 2020Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
-
Patent number: 10624882Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.Type: GrantFiled: December 29, 2017Date of Patent: April 21, 2020Assignee: Aerie Pharmaceuticals, Inc.Inventors: Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, Jr., Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young
-
Patent number: 10624904Abstract: The disclosure teaches precisely engineered biodegradable drug delivery systems and methods of making and utilizing such systems. In aspects, the biodegradable drug delivery systems taught herein comprise intravitreal ocular implants suitable for delivery of corticosteroids to the posterior segment of a human eye. The intravitreal ocular implants described herein have a desired extended drug release profile suitable for treating inflammation of the human eye.Type: GrantFiled: July 22, 2016Date of Patent: April 21, 2020Assignee: Aerie Pharmaceuticals, Inc.Inventors: Stuart Williams, Sanjib Kumar Das, Tomas Navratil, Melissa Sandahl, Janet Tully, Rozemarijn Verhoeven
-
Patent number: 10588901Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.Type: GrantFiled: May 3, 2018Date of Patent: March 17, 2020Assignee: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
-
Patent number: 10568878Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.Type: GrantFiled: February 21, 2018Date of Patent: February 25, 2020Assignee: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
-
Patent number: 10550087Abstract: Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.Type: GrantFiled: November 17, 2015Date of Patent: February 4, 2020Assignee: Aerie Pharmaceuticals, Inc.Inventors: Jill Marie Sturdivant, Mitchell A. deLong, Gilles Chambournier, Michael G. Pamment, Victor Fedij
-
Patent number: 10532993Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.Type: GrantFiled: September 21, 2018Date of Patent: January 14, 2020Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
-
Patent number: 10472327Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.Type: GrantFiled: December 29, 2017Date of Patent: November 12, 2019Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
-
Patent number: 10316029Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.Type: GrantFiled: March 30, 2018Date of Patent: June 11, 2019Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Jill M. Sturdivant, Susan M. Royalty
-
Patent number: 10174017Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.Type: GrantFiled: March 16, 2018Date of Patent: January 8, 2019Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Jill M. Sturdivant, Susan M. Royalty
-
Patent number: 10112920Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.Type: GrantFiled: December 15, 2017Date of Patent: October 30, 2018Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
-
Patent number: 9993470Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.Type: GrantFiled: June 19, 2017Date of Patent: June 12, 2018Assignee: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
-
Patent number: 9963432Abstract: Disclosed are alpha-aryl-beta-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing isoquinoline amide compounds.Type: GrantFiled: March 31, 2017Date of Patent: May 8, 2018Assignee: Aerie Pharmaceuticals, Inc.Inventors: Jill M. Sturdivant, Mitchell A. deLong, Susan M. Royalty
-
Patent number: 9951059Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.Type: GrantFiled: February 28, 2017Date of Patent: April 24, 2018Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
-
Patent number: 9931336Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.Type: GrantFiled: August 15, 2016Date of Patent: April 3, 2018Assignee: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
-
Patent number: 9890123Abstract: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.Type: GrantFiled: June 9, 2016Date of Patent: February 13, 2018Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Susan M. Royalty, Jill Marie Sturdivant, Geoffrey Richard Heintzelman
-
Patent number: 9884840Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.Type: GrantFiled: November 2, 2016Date of Patent: February 6, 2018Assignee: Aerie Pharmaceuticals, Inc.Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
-
Patent number: 9849122Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.Type: GrantFiled: April 29, 2016Date of Patent: December 26, 2017Assignee: Aerie Pharmaceuticals, Inc.Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
-
Patent number: 9840468Abstract: Described are methods for the preparation of 6-aminoisoquinoline, a useful intermediate compound in the synthesis of kinase inhibitors.Type: GrantFiled: December 30, 2016Date of Patent: December 12, 2017Assignee: Aerie Pharmaceuticals, Inc.Inventors: Gilles Chambournier, Mitchell A. deLong